Table 2. Correlation of QKI-5 with clinicopathologic characteristics of patients with PCa.

Variable	N	QKI mRNA expression				P
		Reduced	%	Unreduced	%
Age at diagnosis						0.954a
≥60	120	83	69.20%	37	30.80%
<60	64	44	68.80%	20	31.20%
Gleason score						<0.001b
2:4	27	11	40.70%	16	59.30%
5:7	63	39	61.90%	24	38.10%
8:10	94	77	81.90%	17	18.10%
PSA in serum						0.457a
>20 ng/ml	156	106	67.90%	50	32.10%
≤20 ng/ml	28	21	75.00%	7	25.00%
Differentiation status						<0.001a
Well	25	9	36.00%	16	64.00%
Moderately	66	43	65.20%	23	34.80%
Poor and undifferentiatedly	93	75	80.60%	18	19.40%
Depth of invasion						0.050a
pT1+pT2	52	28	53.80%	24	46.20%
pT3+pT4	132	99	75.00%	33	25.00%
Lymph node metastasis						0.001a
Absent (N0)	81	46	56.80%	35	43.20%
Present (N1:3)	103	81	78.60%	22	21.40%
Distant metastasis						0.001a
Absent (M0)	142	87	62.30%	55	37.70%
Present (M1)	42	40	95.20%	2	4.80%
pTNM stage						<0.001b
I	21	5	23.80%	16	76.20%
II	27	16	59.30%	9	40.70%
III	79	59	74.70%	18	25.30%
IV	57	47	82.50%	10	17.50%

^aP value when expression levels were compared using the Pearson χ² test. ^bP value when expression levels were compared using Mann–Whitney U test.